Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GYS1 | P13807 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759569 | 0.87 | GYS1 (0.53) | CNR1GYS1FFAR1 | |
| SCHEMBL12595375 | 0.84 | GSTP1 (0.54) | CNR1FFAR1AKR1B1MAOBMAOA | |
| SCHEMBL16841040 | 0.76 | MAOB (0.49) | CNR1MAOBMAOA | |
| SCHEMBL28587983 | 0.75 | XDH (0.61) | MAOBMAOA | |
| SCHEMBL2012370 | 0.73 | GYS1 (0.52) | GYS1MAOBGSTP1 | |
| SCHEMBL188284 | 0.72 | MAOB (0.55) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL1767090 | 0.72 | MAOB (0.56) | GYS1MAOBGSTP1 | |
| SCHEMBL28572338 | 0.72 | XDH (0.63) | MAOBMAOA | |
| SCHEMBL4753464 | 0.72 | MAOB (0.74) | MAOBMAOA | |
| SCHEMBL21158608 | 0.71 | PTGDR2 (0.48) | CNR1FFAR1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947728-B1 | Indole and indazole analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2011057959-A1 | INDOLE AND INDAZOLE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GSK3B | CNR1 1963/4885CNR2 1810/4885GYS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.